Navigation Links
KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
Date:7/15/2013

NORTH LIBERTY, Iowa, July 15, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Gordon K. "Rusty" Johnson as Chief Operating Officer (COO) and Chief Financial Officer (CFO). 

As COO and CFO of KemPharm, Mr. Johnson will join KemPharm's executive management team and will be responsible for enhancing the company's financial and operational initiatives and the ongoing development of KP201.  KP201 is KemPharm's lead clinical candidate in development for the treatment of acute moderate to moderately severe pain. KemPharm anticipates submitting a new drug application (NDA) for KP201 to the FDA in the second quarter of 2014.

Travis C. Mickle, Ph.D., president and CEO of KemPharm, commented, "Adding an executive with Rusty's industry knowledge and transactional expertise is a tremendous achievement for KemPharm as we continue to advance the clinical and regulatory development of KP201 and our entire pipeline.  In particular, Rusty's diverse investment banking background is exactly what KemPharm needs to propel our strategy forward as we seek to bring a new class of prescription opioid to the market; one that simultaneously deters abuse and reduces opioid-induced constipation."

Mr. Johnson's career is highlighted by over 30 years of investment banking experience including strategic financial advisory, corporate finance and sales & trading responsibilities at firms that include Piper Jaffray & Co.; WR Hambrecht + Co; Deutsche Bank; Kidder, Peabody & Co. and Credit Suisse First Boston.

Mr. Johnson has led a wide variety of public offerings, private financings and advisory assignments across multiple industries as well as for life sciences companies including, most recently, ADMA Biologics,
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
4. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
5. BioStorage Technologies Appoints New Member to Board of Directors
6. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
9. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. Veracyte Appoints Mark Spring as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / 20% ... high-single-digit growth in China , as well as solid contributions ... Europe / Middle East / ... showed gains in Germany , Turkey ... CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on demand ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, ... launch of their 2nd generation cell therapy POD® design. The 2nd generation portfolio ... also represents a new POD® design. , “G-CON first offered our miniPOD ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... 7 Codexis, Inc. today announced,a licensing agreement with ... product, using a proprietary Codexis,biocatalyst. Teva, the largest ... of this generic product. The product is one ... States. , Under the agreement, ...
... Calif., Jan. 7 Intradigm Corporation, a leading,developer ... that the company has closed the final tranche ... the $2.9 million tranche, with,existing investor, Lilly Ventures, ... the total Series B financing to $21.4 million. ...
... Abaxis, Inc. (Nasdaq: ABAX ), a ... for both the medical and veterinary markets, announced ... agreement for co-exclusive worldwide rights in the field ... for certain technologies pertaining to lateral flow immunoassay ...
Cached Biology Technology:Codexis, Teva in Licensing Agreement Final 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 2ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 3
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading ... for its second quarter ended June 30, 2015.  ... million, a decrease of 33% compared to $6.8 million in ... quarter of 2015 was $0.3 million, or $0.01 per diluted ... share, in the same period a year ago.  ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... skull-splitting pain. Scientists have found evidence that the headaches ... parts of the brain starved for oxygen and altering ... the work by neuroscientists at the University of Rochester ... , The scientists say the work makes it ...
... new study appearing in the May issue of The ... geologists must account for when examining dinosaur tracks. The ... family of dinosaurs that includes the T. Rex and ... effects of many different types of erosion on these ...
... more than just making pie, according to new data from ... researchers and presented today at a major scientific meeting. ... animals that received powdered tart cherries in their diet had ... the liver, lower oxidative stress and increased production of a ...
Cached Biology News:Mice with a migraine show signs of brain damage 2Mice with a migraine show signs of brain damage 3Mice with a migraine show signs of brain damage 4Mice with a migraine show signs of brain damage 5How to look at dinosaur tracks 2A cherry on top: Tart cherries may alter heart/diabetes factors 2A cherry on top: Tart cherries may alter heart/diabetes factors 3A cherry on top: Tart cherries may alter heart/diabetes factors 4
... Caliper's iLink makes it easy to supply ... instruments. Developed with operator convenience in mind, ... shoot' ease of use. The iLink software ... for assays or sub-assays, that can be ...
... As research demands continue to grow, ... more spectral information has become necessary, especially ... spectral colors. The innovative C1si Confocal Microscope ... speed and spectral capability not available in ...
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The LAS-3000 provides significantly improved system ... applications including: fluorescence, chemifluorescence, chemiluminescence, and ...
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
Biology Products: